Replimune Shares Plunge Following Regulatory Setback

Regulatory Pathway Blocked

Replimune Group Inc. finds itself navigating turbulent market conditions as its stock value experiences a dramatic collapse. The biotechnology firm witnessed its equity plummet more than 40% in a single trading session, reflecting severe investor disapproval after additional regulatory obstacles emerged for its lead cancer therapy.

The company’s recent meeting with the U.S. Food and Drug Administration (FDA) in mid-September delivered another significant blow. Regulatory officials declined to outline a viable accelerated approval route for RP1, Replimune’s investigational oncolytic immunotherapy, when used in combination with nivolumab for advanced melanoma. This development compounds earlier disappointment from July, when the agency issued a Complete Response Letter regarding the therapy’s application.

Market Reaction and Mounting Losses